Skip to main
DOCS

Doximity (DOCS) Stock Forecast & Price Target

Doximity (DOCS) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 29%
Buy 24%
Hold 48%
Sell 0%
Strong Sell 0%

Bulls say

Doximity is likely to face revenue headwinds in the coming years due to a declining number of pharmaceuticals under patent, reducing the need for high levels of marketing spend on its platform. This could negatively impact the company's core marketing solutions segment, and its recent appointment of a new CFO and president may be a response to these challenges. In addition, the company has announced weaker market conditions and reduced market share gains, cutting their FY27 and FY28 estimates, with F1Q guidance below consensus. This is likely due to ongoing policy uncertainty and increased macro risk, as well as pharma companies shifting towards shorter-duration spend commitments resulting in limited visibility.

Bears say

Doximity is facing significant challenges due to market pressure and investments in AI that have led to lower than expected guidance for FY27 and 1QF27, despite projected revenue growth of 17.5%. In addition, their EBITDA guidance is also lower than expected, but they plan to maintain a high adjusted EBITDA margin. However, concerns about inconsistent results and competition have prompted a downgrade to Neutral, while competitor VEEV has a Buy rating and is successfully navigating industry challenges. Despite risks in the regulated healthcare industry, DOCS may see potential upside from increased demand for AI solutions and new leadership in a post-pandemic world.

Doximity (DOCS) has been analyzed by 21 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 24% recommend Buy, 48% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Doximity (DOCS) Forecast

Analysts have given Doximity (DOCS) a Buy based on their latest research and market trends.

According to 21 analysts, Doximity (DOCS) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Doximity (DOCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.